The gut microbiota ecology: a new opportunity for the treatment of metabolic diseases ?
Open accessAbstract
In humans, the intestinal microflora is inherited from our parents and from the environment. It has established an ecological mutualism with the host, allowing each organism to benefit from the symbiotic relationship. Based on recent evidence, some molecular mechanisms for the role of intestinal microflora on the control of energy metabolism have been proposed. During metabolic diseases such as obesity and diabetes, it has been proposed that an imbalance between the two dominant groups of beneficial bacteria, the Bacteroidetes and the Firmicutes, generates signals controlling the expression of genes by the epithelial intestinal cells. Genes involved in lipid metabolism such as the Fast Induced Adipocyte Factor have been considered as putative targets. In addition, bacterial extracts such as the lipopolysaccharides control the tone of the innate immune system thus regulating the general inflammatory status, insulin resistance, and adipose tissue plasticity. Therefore, strategies aimed at controlling the ecological mutualism between intestinal microflora and the host should lead to a new era of therapeutic and health benefits.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The low-grade chronic inflammation state in metabolic syndrome has been explained by metabolic endotoxemia resulting from gut dysbiosis.
“Primary, the low-grade chronic inflammation state in MetS has been explained by the metabolic endotoxemia that was a result of gut dysbiosis [6,7].”
From Effects of Regular Kefir Consumption on Gut Microbiota in Patients with Metabolic Syndrome: A Parallel-Group, Randomized, Controlled Study (2019) · cites this paper as [6]
Cited by
Sorted by citations
Chronic Inflammation in Obesity and the Metabolic Syndrome
Monteiro, R., & Azevedo, I. (2010) · Mediators of Inflammation · doi:10.1155/2010/289645 · Cited by 1,186 · see citing works
“[107] R.”
ResultStenman, L. K., Lehtinen, M. J., Meland, N., Christensen, J. E., Yeung, N., Saarinen, M. T., Courtney, M., Burcelin, R., Lähdeaho, M.-L., Linros, J., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.10.036 · Cited by 177 · see citing works
Self-citationBELLIKCI-KOYU, E., SARER-YUREKLI, B. P., AKYON, Y., AYDIN-KOSE, F., KARAGOZLU, C., OZGEN, A. G., BRINKMANN, A., NITSCHE, A., ERGUNAY, K., YILMAZ, E., et al. (2019) · Nutrients · doi:10.3390/nu11092089 · Cited by 144 · see citing works
“Primary, the low-grade chronic inflammation state in MetS has been explained by the metabolic endotoxemia that was a result of gut dysbiosis [6,7].”
BackgroundFar from the eyes, close to the heart: dysbiosis of gut microbiota and cardiovascular consequences
Serino, M., Blasco-Baque, V., Nicolas, S., & Burcelin, R. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0540-1 · Cited by 93 · see citing works
Self-citation
- Authors
- Burcelin, R.
- Venue
- Frontiers in Bioscience
- Publisher
- IMR Press
- Published
- 2009
- Volume
- 14
- Issue
- 1
- Pages
- 5107
- ISSN
- 1093-4715 (ISSN-L)
- 1093-9946
- DOI
- 10.2741/3589
- OpenAlex
- W2327646444
- Cited by
- 55
- References
- 0
- Citations by year
- 2024: 1 · 2023: 4 · 2022: 1 · 2021: 1 · 2019: 2 · 2018: 2 · 2017: 2 · 2016: 2 · 2015: 2 · 2014: 7 · 2013: 5 · 2012: 9
- FWCI
- 0.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Frontiers in bioscience (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Keywords
- gut microbiota, host-microbe mutualism, energy metabolism, obesity, diabetes mellitus, Bacteroidetes, Firmicutes, FIAF, lipopolysaccharide, innate immunity, insulin resistance, adipose tissue plasticity, lipid metabolism, metabolic disorders
- MeSH terms
- Energy Metabolism, Biological Evolution, Food, Humans, Inflammation, Insulin Resistance, Intestines, Lipopolysaccharides, Metabolic Diseases, Models, Biological, Symbiosis, Weight Gain, Ecosystem, Probiotics, Metagenome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review